Details for Patent: 11,298,349

Which drugs does patent 11,298,349 protect, and when does it expire?

Patent 11,298,349 protects COMETRIQ and CABOMETYX and is included in two NDAs.

This patent has forty-three patent family members in twenty-one countries.

Summary for Patent: 11,298,349

Title:	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Abstract:	The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
Inventor(s):	Jo Ann Wilson, Khalid Shah
Assignee:	Exelixis Inc
Application Number:	US17/170,275
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,298,349
Patent Claim Types: see list of patent claims	Composition; Process; Dosage form;

Drugs Protected by US Patent 11,298,349

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-001	Nov 29, 2012		RX	Yes	No			Y
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-002	Nov 29, 2012		RX	Yes	Yes			Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No			Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-002	Apr 25, 2016		RX	Yes	No			Y

International Family Members for US Patent 11,298,349

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	085155
Australia	2012214322
Australia	2017204877
Australia	2019203745